These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24740738)

  • 1. Revising the role of the androgen receptor in breast cancer.
    Fioretti FM; Sita-Lumsden A; Bevan CL; Brooke GN
    J Mol Endocrinol; 2014 Jun; 52(3):R257-65. PubMed ID: 24740738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
    Grellety T
    Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
    Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the androgen receptor in prostate cancer.
    Culig Z
    Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
    Héquet D; Mzoughi S; Rouzier R; Guccione E
    Bull Cancer; 2017 Apr; 104(4):363-369. PubMed ID: 28216075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial [
    Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
    Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
    Knudsen KE; Scher HI
    Clin Cancer Res; 2009 Aug; 15(15):4792-8. PubMed ID: 19638458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
    Ray S; Johnston R; Campbell DC; Nugent S; McDade SS; Waugh D; Panov KI
    Gene; 2013 Aug; 526(1):46-53. PubMed ID: 23608168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
    Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
    Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
    Rhanine Y; Bonnefoi H; Goncalves A; Debled M; Le Moulec S; Bonichon N; Macgrogan G; Arnedos M; Dubroca-Dehez B; Grellety T
    Breast; 2024 Feb; 73():103667. PubMed ID: 38160476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.